The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer

Published:2015-11 Issue:17 Volume:51 Page:2562-2569
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

van Soest R.J.,Nieuweboer A.J.M.,de Morrée E.S.,Chitu D.,Bergman A.M.,Goey S.H.,Bos M.M.,van der Meer N.,Hamberg P.,de Wit R.,Mathijssen R.H.J.

Funder

Sanofi

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

3. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial;European Urology Oncology;2024-08

2. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15

3. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Oncology;2023-12-01

4. Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer;Journal of Clinical Oncology;2023-11-10

5. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis;Urologic Oncology: Seminars and Original Investigations;2023-04